TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9215435

Group type: EXPERIMENTAL
Intervention: Traditional case-control studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case-crossover design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrid designs (case-control, case-crossover, cohort)
Number of subjects: 0
Study: 8480824

Group type: EXPERIMENTAL
Intervention: 20 mg of fluoxetine
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: 60 mg of fluoxetine
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 3505173

Group type: EXPERIMENTAL
Intervention: Billroth II gastrojejunostomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Roux-en-Y gastrojejunostomy
Number of subjects: 20
Study: 31768470

Group type: EXPERIMENTAL
Intervention: Lay navigator-led early palliative care coaching intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 29143427

Group type: EXPERIMENTAL
Intervention: Educational program using printed educational material
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 17
Study: 27113608

Group type: COMPARATOR
Intervention: Healthy controls (Group 1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ankle osteoarthritis (Group 2)
Number of subjects: 33
Study: 24703723

Group type: EXPERIMENTAL
Intervention: Taxane-containing treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Luminal group
Number of subjects: 0

Group type: COMPARATOR
Intervention: HR-negative disease
Number of subjects: 0
Study: 22661453

Group type: EXPERIMENTAL
Intervention: Placebo metered-dose inhaler
Number of subjects: 21

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Inhaler therapy (informed it was inert)
Number of subjects: 21
Study: 20226408

Group type: EXPERIMENTAL
Intervention: 2D‐SHG
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 3D‐SHG
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Diagnostic hysteroscopy
Number of subjects: 70
Study: 18784099

Group type: EXPERIMENTAL
Intervention: Surgical lavage and arthroscopic debridement together with optimized physical and medical therapy
Number of subjects: 178

Group type: COMPARATOR
Intervention: Physical and medical therapy alone (Control)
Number of subjects: 178
Study: 16242437

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (5% glucose solution)
Number of subjects: 20
Study: 12066420

Group type: EXPERIMENTAL
Intervention: Time intervals of 1.85 to 6.45 seconds with a memory task
Number of subjects: 0
Study: 10586554

Group type: EXPERIMENTAL
Intervention: Group PEG (propofol/epidural/nitrous oxide)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Group PE (propofol/epidural)
Number of subjects: 88
Study: 8767241

Group type: EXPERIMENTAL
Intervention: Etomidate (in lipid emulsion) 0.25 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol 1.5 mg/kg
Number of subjects: 40
Study: 1897306

Group type: EXPERIMENTAL
Intervention: Irregular anti-diphtheria vaccination (incomplete/irregular doses)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Regular vaccination (three toxoid doses) and one or more booster doses
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Irregularly vaccinated children
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: All children (both regular and irregular)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Regularly or irregularly administered toxoid doses
Number of subjects: 204
Study: 6225405

Group type: EXPERIMENTAL
Intervention: Clorgyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroconvulsive treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desipramine and Clorgyline (combined case)
Number of subjects: 0
Study: 31419229

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 2102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study: 27321067

Group type: EXPERIMENTAL
Intervention: Client‐centred activity of daily living intervention (CADL)
Number of subjects: 33
Study: 27196493

Group type: EXPERIMENTAL
Intervention: Tibial intraosseous access using NIO device
Number of subjects: 42

Group type: COMPARATOR
Intervention: Humeral intraosseous access using NIO device
Number of subjects: 42
Study: 24189504

Group type: EXPERIMENTAL
Intervention: Very Late Stent Thrombosis (VLST)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Early Stent Thrombosis (EST)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Late Stent Thrombosis (LST)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stent (DES)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Bare-Metal Stent (BMS)
Number of subjects: 152
Study: 22595038

Group type: EXPERIMENTAL
Intervention: donepezil (5 mg q.d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 20933082

Group type: EXPERIMENTAL
Intervention: Garlic extract for 21 days
Number of subjects: 0
Study: 17428104

Group type: EXPERIMENTAL
Intervention: Oral satraplatin plus prednisone
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Single-agent satraplatin
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Satraplatin
Number of subjects: 600
Study: 15632662

Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography (DOB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exercise echocardiography (EX)
Number of subjects: 20
Study: 12806756

Group type: EXPERIMENTAL
Intervention: TEAM group
Number of subjects: 32

Group type: COMPARATOR
Intervention: No TEAM group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Post-course questionnaire
Number of subjects: 32
Study: 10477983

Group type: EXPERIMENTAL
Intervention: K‐512 (Fuji III LC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Delton Opaque
Number of subjects: 14
Study: 8943507

Group type: EXPERIMENTAL
Intervention: Crinone 8% (90 mg vaginal progesterone per day)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Utrogestan (300 mg oral micronized progesterone)
Number of subjects: 283
Study: 1647293

Group type: EXPERIMENTAL
Intervention: Naloxone (0.5-1.0 mg, i.m.) administered at 6, 30 and 54 h after methadone pre-treatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (0.5-1.0 mg, i.m.) administered only at 54 h after methadone pre-treatment
Number of subjects: 6
Study: 6190441

Group type: EXPERIMENTAL
Intervention: Inosiplex
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Inosiplex and Placebo
Number of subjects: 58
Study: 31974589

Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 34

Group type: COMPARATOR
Intervention: No haemodialysis (Control)
Number of subjects: 34
Study: 29717621

Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using The Internet
Number of subjects: 1149

Group type: COMPARATOR
Intervention: HealthWatch
Number of subjects: 1149
Study: 26614250

Group type: EXPERIMENTAL
Intervention: Carbon monoxide (CO) exposure from woodsmoke, measured with 72 hour personal monitoring at study enrollment.
Number of subjects: 817
Study: 24552155

Group type: EXPERIMENTAL
Intervention: Albiglutide 15 mg weekly
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg weekly
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg biweekly
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 24204044

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory treatment
Number of subjects: 0
Study: 19995366

Group type: EXPERIMENTAL
Intervention: Intralesional vincristine (0.3-0.8 mm injected in a single nodule)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (similar lesion kept under clinical observation)
Number of subjects: 151
Study: 18214667

Group type: EXPERIMENTAL
Intervention: Cost diary for families with an anxious child
Number of subjects: 118

Group type: COMPARATOR
Intervention: Families from the general population
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Bottom-up approach for clinically anxious children
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Clinical anxiety disorders in childhood
Number of subjects: 118
Study: 17684879

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 15 microg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 12702897

Group type: EXPERIMENTAL
Intervention: Valproic acid (500-2500 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11028111

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8863693

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (up to 0.15 mg/kg body weight)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous pethidine (up to 1.5 mg/kg body weight)
Number of subjects: 20
Study: 1323160

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate combined with oral verapamil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sodium stibogluconate only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pentamidine
Number of subjects: 40
Study: 6344283

Group type: EXPERIMENTAL
Intervention: Cefoxitin (1 gram intravenously at the time of cord clamping and again four and eight hours later)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29097438

Group type: EXPERIMENTAL
Intervention: Whole grain diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Refined grain diet
Number of subjects: 60
Study: 30998881

Group type: EXPERIMENTAL
Intervention: Assessment aid (printed copy of GCS scoring table)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No assessment aid (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Assessment aid
Number of subjects: 32
Study: 27306347

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, amoxicillin, and omeprazole (CAO)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Amoxicillin, furazolidone, and omeprazole (FAO)
Number of subjects: 66
Study: 24401159

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (BoNT‐A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 0
Study: 23027721

Group type: EXPERIMENTAL
Intervention: stationary cycling to music
Number of subjects: 30

Group type: COMPARATOR
Intervention: interactive video game cycling
Number of subjects: 30
Study: 19679057

Group type: EXPERIMENTAL
Intervention: HER2 testing
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: HER2 testing with ER status information
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: HER2 testing with tumor grade information
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: HER2 testing with tumor size information
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: HER2 testing with lymph node status information
Number of subjects: 1364
Study: 17356388

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) > or =90 mg/L
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Monocyte chemotactic protein-1 (MCP-1)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Interleukin-8 (IL-8)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combination of 2 or 3 markers (CRP, MCP-1, IL-8)
Number of subjects: 76

Group type: COMPARATOR
Intervention: CRP, IL-8, and MCP-1 levels
Number of subjects: 76
Study: 15712717

Group type: EXPERIMENTAL
Intervention: Customized filtering technique for heart rate variability analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fast Fourier Transformation (FFT)
Number of subjects: 0
Study: 11282797

Group type: EXPERIMENTAL
Intervention: Higher serum vitamin B(6) levels
Number of subjects: 300

Group type: COMPARATOR
Intervention: Serum folate
Number of subjects: 300

Group type: COMPARATOR
Intervention: Vitamin B(12)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Homocysteine
Number of subjects: 300
Study: 9924560

Group type: EXPERIMENTAL
Intervention: CFC-free metered dose inhaler (Airomir®)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Current inhaler (CFC-containing)
Number of subjects: 201
Study: 8028034

Group type: EXPERIMENTAL
Intervention: DFMO 0.25 g/m2 for 28 days
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: DFMO 0.5 g/m2 for 28 days
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: DFMO 0.75 g/m2 for 28 days
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: DFMO 1.0 g/m2 for 28 days
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: DFMO 1.5 g/m2 for 28 days
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: DFMO 2.0 g/m2 for 28 days
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: DFMO 3.0 g/m2 for 28 days
Number of subjects: 111
Study: 2659383

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 200 mg x 3 daily for patients <30 kg or 400 mg x 2 daily for patients >30 kg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 1093604

Group type: EXPERIMENTAL
Intervention: Topical cephaloridine
Number of subjects: 192

Group type: COMPARATOR
Intervention: Povidone-iodine spray
Number of subjects: 192
Study: 30611913

Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 131

Group type: COMPARATOR
Intervention: OPE
Number of subjects: 131
Study: 28002684

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg‐1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (wheat flour)
Number of subjects: 23
Study: 25218817

Group type: EXPERIMENTAL
Intervention: Isokinetic knee strength measures
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Eccentric isokinetic measures
Number of subjects: 82
Study: 23706654

Group type: EXPERIMENTAL
Intervention: GSV surgery with high ligation of the SFJ (group A, n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: GSV surgery without high ligation of the SFJ (group B, n = 60)
Number of subjects: 120
Study: 21127475

Group type: EXPERIMENTAL
Intervention: α-cyclodextrin (α-CD)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 41
Study: 19168019

Group type: EXPERIMENTAL
Intervention: Oral lyophilisate (Minirinmelt)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Desmopressin tablets (0.2 or 0.4 mg)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Both formulations (lyophilisate and tablet)
Number of subjects: 214
Study: 17360873

Group type: EXPERIMENTAL
Intervention: Tafenoquine (200 mg base/day for 3 days, followed by 200 mg/week for 8 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Chloroquine with 8 weeks of tafenoquine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Chloroquine with primaquine (22.5 mg/day for 14 days)
Number of subjects: 27
Study: 15205859

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA
Number of subjects: 23
Study: 11474382

Group type: EXPERIMENTAL
Intervention: Ultraflex stent
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Flamingo Wallstent
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gianturco‐Z stent
Number of subjects: 100

Group type: COMPARATOR
Intervention: All stents
Number of subjects: 100
Study: 9510582

Group type: EXPERIMENTAL
Intervention: geG 0.5 mg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: geG 0.25 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: HBB 20 mg
Number of subjects: 264
Study: 7857751

Group type: EXPERIMENTAL
Intervention: ACE-inhibitor (enalapril) added to conventional heart failure therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of hydralazine and nitrates in addition to conventional treatment
Number of subjects: 0
Study: 3053605

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28676100

Group type: EXPERIMENTAL
Intervention: G-BM
Number of subjects: 101

Group type: COMPARATOR
Intervention: G-PBSC
Number of subjects: 101
Study: 25055078

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (12 weeks of exercise training and 1 year of psychoeducational follow-up)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196
Study: 23258423

Group type: EXPERIMENTAL
Intervention: Raw mother's own milk
Number of subjects: 303

Group type: COMPARATOR
Intervention: Pasteurized mother's own milk
Number of subjects: 303
Study: 21497631

Group type: EXPERIMENTAL
Intervention: 15 or 30 μg of inactivated influenza vaccine, followed by a 15 μg booster vaccine
Number of subjects: 731
Study: 18271716

Group type: EXPERIMENTAL
Intervention: One-shot procedure
Number of subjects: 31

Group type: COMPARATOR
Intervention: Telescopic procedure
Number of subjects: 31
Study: 17315706

Group type: EXPERIMENTAL
Intervention: Levitra (vardenafil; 5 mg per os each other day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no Levitra)
Number of subjects: 60
Study: 14520773

Group type: EXPERIMENTAL
Intervention: Powered toothbrush (SynchroSonic)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 70
Study: 12036804

Group type: EXPERIMENTAL
Intervention: Nutrient-enriched preterm formula
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard formula or banked breast milk
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Human milk intake
Number of subjects: 197
Study: 9848041

Group type: EXPERIMENTAL
Intervention: Limulus amebocyte lysate (LAL) assay using QCL‐1000 kit
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Limulus amebocyte lysate (LAL) assay
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients with concomitant fungal infections
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients with elevated LAL
Number of subjects: 45
Study: 7837161

Group type: EXPERIMENTAL
Intervention: Musculoskeletal complaints (pain at various sites)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knee pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upper back pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ankle/foot pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shoulder pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Back pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of nonsteroidal antiinflammatory drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain limiting activities
Number of subjects: 0
Study: 2764545

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 500 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 1,000 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 1,500 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 2,000 mg
Number of subjects: 16
Study: 360245

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 27
Study: 30565981

Group type: EXPERIMENTAL
Intervention: Group S (short) - played 3 hours during the last week of the 6-week intervention period
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group L (long) - played 18 hours over 6 weeks
Number of subjects: 52
Study: 28319696

Group type: EXPERIMENTAL
Intervention: Physical activity without treatment rationale
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Physical activity with treatment rationale
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Behavioral activation without treatment rationale
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Behavioral activation with treatment rationale
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 286
Study: 25283362

Group type: EXPERIMENTAL
Intervention: Stand-alone anchored PEEK cage (PREVAIL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: PEEK cage with plating
Number of subjects: 50
Study: 23475289

Group type: EXPERIMENTAL
Intervention: Isoflavone 70 mg/day for 12 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 20733582

Group type: COMPARATOR
Intervention: Solid gelatin (6g)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Liquid gelatin (6g)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sucrose (75g)
Number of subjects: 43

Group type: COMPARATOR
Intervention: G50:F50 mixture (75g)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Solid whey protein (50g)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Liquid whey protein (50g)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (water for experiments 1 and 3, calorie-free sweetened water for experiment 2)
Number of subjects: 43
Study: 18768245

Group type: EXPERIMENTAL
Intervention: Magnesium (360mg daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 16522911

Group type: EXPERIMENTAL
Intervention: Micronized dispersible ferric pyrophosphate (MDFP) in wheat-based meal
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ferrous sulfate in wheat-based meal
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MDFP in wheat-based meal with ascorbic acid (4:1 molar ratio)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ferrous sulfate in wheat-based meal with ascorbic acid (4:1 molar ratio)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MDFP added to rice meal at feeding time
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ferrous sulfate in rice meal
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MDFP extruded into artificial rice grains
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ferrous sulfate in unprocessed rice
Number of subjects: 26
Study: 12546349

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate
Number of subjects: 957
Study: 10665553

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (target international normalised ratio 3.0‐4.5, n=1339)
Number of subjects: 2690

Group type: COMPARATOR
Intervention: Aspirin (80 mg daily, n=1351)
Number of subjects: 2690
Study: 9065637

Group type: EXPERIMENTAL
Intervention: Septoplasty supplemented with anterior inferior turbinoplasty
Number of subjects: 50

Group type: COMPARATOR
Intervention: Septoplasty alone
Number of subjects: 50
Study: 8373269

Group type: EXPERIMENTAL
Intervention: 2-cm surgical margins
Number of subjects: 486

Group type: COMPARATOR
Intervention: 4-cm surgical margins
Number of subjects: 486